Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Colorcon
Merck
Moodys
Mallinckrodt

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201281

See Plans and Pricing

« Back to Dashboard

NDA 201281 describes JENTADUETO, which is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from two suppliers. There are fifteen patents protecting this drug and two Paragraph IV challenges. Additional details are available on the JENTADUETO profile page.

The generic ingredient in JENTADUETO is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.
Summary for 201281
Tradename:JENTADUETO
Applicant:Boehringer Ingelheim
Ingredient:linagliptin; metformin hydrochloride
Patents:13
Pharmacology for NDA: 201281
Suppliers and Packaging for NDA: 201281
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
JENTADUETO linagliptin; metformin hydrochloride TABLET;ORAL 201281 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0146 0597-0146-18 180 TABLET, FILM COATED in 1 BOTTLE (0597-0146-18)
JENTADUETO linagliptin; metformin hydrochloride TABLET;ORAL 201281 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0146 0597-0146-60 60 TABLET, FILM COATED in 1 BOTTLE (0597-0146-60)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2.5MG;500MG
Approval Date:Jan 30, 2012TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Apr 2, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
Patent:  Start TrialPatent Expiration:Feb 2, 2019Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN
Patent:  Start TrialPatent Expiration:Feb 2, 2019Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN

Expired US Patents for NDA 201281

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Medtronic
Johnson and Johnson
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.